Advertisements


Marker Therapeutics reports interim results of MultiTAA T Cell Therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 21st, 2019

Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study.....»»

Category: earningsSource: benzingaAug 14th, 2019

Marker Therapeutics: A Cell Therapy Biotech Thinking Outside Of The Box

Marker Therapeutics: A Cell Therapy Biotech Thinking Outside Of The Box.....»»

Category: topSource: seekingalphaJun 19th, 2019

TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today reported financial re.....»»

Category: earningsSource: benzingaApr 1st, 2019

TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade

TapImmune, Inc. (NASDAQ: TPIV) will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade.....»»

Category: blogSource: benzingaJun 2nd, 2018

Global Blood Therapeutics shares drop after late-stage data for sickle cell disease treatment

Global Blood Therapeutics Inc. shares dropped as much as 12% in premarket trade on Wednesday after the company reported results for a late-stage trial of sickle cell disease therapy, and said that it met with the U.S. Food and Drug Ad.....»»

Category: topSource: marketwatchJun 27th, 2018

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results -Ongoing Exploration of Strategic Opportunities- -Continued Progress in Stem-to-T-Cell.....»»

Category: earningsSource: benzingaAug 13th, 2018

Rancho Cordova"s Cesca Therapeutics reports $27.2 million loss on impairment of assets

Cesca Therapeutics Inc., a Rancho Cordova-based cell therapy company, said it incurred $27.2 million in charges against earnings last quarter for impairment in the value of assets. The impairment charges include $12.7 million to goodwill and $14.5.....»»

Category: topSource: bizjournalsAug 13th, 2018

Athersys reports "positive" results from study of MultiStem cell therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 23rd, 2019

Cytori Therapeutics announces results from Cytori Cell Therapy trial published

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 31st, 2019

Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018

LONDON, Feb. 25, 2019 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell thera.....»»

Category: earningsSource: benzingaFeb 25th, 2019

WuXi Biologics Reports Outstanding Interim Results

52.4% Year-on-Year Revenue Growth to RMB1,607.1 Million Net Profit Increased 80.1% Year-on-Year to RMB449.5 Milli.....»»

Category: earningsSource: benzingaAug 19th, 2019

WuXi AppTec Reports First Half 2019 Interim Results

Revenue Accelerated 33.7% Year-Over-Year to RMB 5,894 Million Gross Profit Up 30.0% Year-Over-Year to RMB 2,284 million[1] Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB 1,179 Million .....»»

Category: earningsSource: benzingaAug 19th, 2019

Plus Therapeutics Reports Q2 2019 Financial and Business Results

AUSTIN, Texas, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company") today announced Q2 2019 financial results and provided updates on corporate activities. Q2 201.....»»

Category: earningsSource: benzingaAug 15th, 2019

Gran Colombia Gold Reports Second Quarter and First Half 2019 Results; Raises 2019 Production Guidance and On Track to Meet 2019 Cost Guidance

TORONTO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Gran Colombia Gold Corp. (TSX:GCM, OTCQX:TPRFF) announced today the release of its unaudited interim condensed consolidated financial statements and accompanying managemen.....»»

Category: earningsSource: benzingaAug 14th, 2019

Neuralstem Reports Second Quarter 2019 Fiscal Results

GERMANTOWN, Md., Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, report.....»»

Category: earningsSource: benzingaAug 14th, 2019

Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrin.....»»

Category: earningsSource: benzingaAug 13th, 2019

Sabina Gold & Silver Announces Interim Financial Results for The Quarter Ended June 30, 2019

VANCOUVER, British Columbia, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Sabina Gold & Silver Corp. ("Sabina") or (the "Company") (SBB – TSX/SGSVF – OTCQX) reports the interim financial results for the quarter ended June 30, 2018. "During the quarter.....»»

Category: earningsSource: benzingaAug 12th, 2019

Emmaus Life Sciences Reports Sharply Improved 2019 Second Quarter Financial Results

TORRANCE, Calif., Aug. 12, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (NASDAQ:EMMA), a leader in sickle cell disease treatment, today reported significantly improved financial results at its EMI Holdi.....»»

Category: earningsSource: benzingaAug 12th, 2019

Applied Therapeutics Reports Second Quarter 2019 Financial Results

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today reported financial results for t.....»»

Category: earningsSource: benzingaAug 12th, 2019

Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results

SAN FRANCISCO, Aug. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and .....»»

Category: earningsSource: benzingaAug 12th, 2019